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Abstract
AIM: To evaluate the completion rate and diagnostic
yield of the PillCam SB2-ex in comparison to the
PillCam SB2.
METHODS: Two hundred cases using the 8-h PillCam
SB2 were retrospectively compared to 200 cases using
the 12 h PillCam SB2-ex at a tertiary academic center.
Endoscopically placed capsules were excluded from the
study. Demographic information, indications for capsule
endoscopy, capsule type, study length, completion of
exam, clinically significant findings, timestamp of most
distant finding, and significant findings beyond 8 h
were recorded.
RESULTS: The 8 and 12 h capsule groups were well
matched respectively for both age (70.90 ± 14.19
vs 71.93 ± 13.80, P = 0.46) and gender (45.5% vs
48% male, P = 0.69). The most common indications
for the procedure in both groups were anemia and
obscure gastrointestinal bleeding. PillCam SB2-ex had
a significantly higher completion rate than PillCam SB2
(88% vs 79.5%, P = 0.03). Overall, the diagnostic
yield was greater for the 8 h capsule (48.5% for SB2
vs 35% for SB2-ex, P = 0.01). In 4/70 (5.7%) of
abnormal SB2-ex exams the clinically significant finding
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was noted in the small bowel beyond the 8 h mark.

the PillCam SB2-ex which differs from its predecessor
(PillCam SB2) in that it offers a 12 h operating time
similar to the MiroCam. The PillCam SB2 and the
PillCam SB2-ex have the same size and specifications
[6]
except for the recording time .
While a longer operating time may increase the
rate of complete examinations, defined by passage of
the capsule into the colon during its operating time, it
is still unknown whether the additional 4 h of recording
time will increase diagnostic yield or clinical outcomes.
To answer these questions we investigated the
completion rate and diagnostic yield of the new 12 h
PillCam SB2-ex in comparison to the 8 h PillCam SB2.

CONCLUSION: In our study, we found the PillCam
SB2-ex to have a significantly increased completion
rate, though without any improvement in diagnostic
yield compared to the PillCam SB2.
Key words: PillCam SB2; Capsule endoscopy; Obscure
gastrointestinal bleeding
© The Author(s) 2015. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: The PillCam SB2-ex and the PillCam SB2 have
the same size and specifications, except the PillCam
SB2-ec offers 12 h of operation, 4 more hours than
the original PillCam SB2. There has been no evaluation
regarding the completion rate and diagnostic yield
between these two capsules. We examined 200
cases using the 8-h PillCam SB2 and compared it to
200 cases using the 12 h PillCam SB2-ex. We found
the PillCam SB2-ex to have a significantly increased
completion rate, though without any improvement in
the diagnostic yield compared to the PillCam SB2.

MATERIALS AND METHODS
The study was conducted at North Shore University
Hospital after obtaining institutional review board
approval. There was no external financial support.
Capsules that were placed endoscopically in the
stomach or duodenum were excluded from consi
deration. We conducted a retrospective review of
four hundred consecutive inpatients, 200 of whom
had undergone 8-h PillCam SB2 from 2009 to 2011
and 200 consecutive 12 h PillCam SB2-ex inpatient
exams from 2011 to 2013. No inpatient studies
using the 8-h PillCam SB2 were performed following
the introduction of the 12 h PillCam SB2-ex in our
practice. Demographic information, indications for
capsule endoscopy, capsule type, study length,
completion or incomplete exam (completion defined
as capsule passage into the cecum during the
recording), abnormal capsule findings divided into,
bleeding, Arteriovenous malformation (AVM) (arteriovenous malformation), erosive disease, polyps/
mass, and miscellaneous, timestamp of most distant
finding, and findings beyond 8 h were recorded. All
procedures were read by one of two experienced
gastroenterologists. Standard protocol for inpatients
prior to capsule endoscopy required that each patient
receive nothing but clear liquids by mouth from at
least noon the day before capsule ingestion, and that
they receive nothing by mouth other than medication
and sips of water after midnight the night before
ingestion. There was no standard purgative bowel
prep used at our institution before capsule ingestion.
Two hours after capsule ingestion, the patients were
permitted to have clears and then two hours later
a regular diet if deemed medically appropriate by
the gastroenterology consultant. The primary study
endpoint was the completion rate, defined by passage
of the capsule into the cecum during its operating
time. The secondary endpoint was diagnostic yield,
defined by any finding considered abnormal by the
interpreting gastroenterologist.

Rahman M, Akerman S, DeVito B, Miller L, Akerman M, Sultan
K. Comparison of the diagnostic yield and outcomes between
standard 8 h capsule endoscopy and the new 12 h capsule
endoscopy for investigating small bowel pathology. World J
Gastroenterol 2015; 21(18): 5542-5547 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v21/i18/5542.htm DOI:
http://dx.doi.org/10.3748/wjg.v21.i18.5542

INTRODUCTION
Capsule endoscopy has proven to be an effective
method to investigate small bowel pathology including
Crohn’s disease, unexplained abdominal pain, diarrhea,
[1,2]
and obscure gastrointestinal (GI) bleeding
. Of
these indications, capsule endoscopy has become
the first-line option for evaluation of obscure GI
bleeding which is defined as “overt bleeding and/or
anemia with a negative endoscopic workup including
[3]
complete colonoscopy and gastroscopy” . The PillCam
SB (previously known as the M2A; Given Imaging,
[1,4,5]
Yokneam, Israel) which was introduced in 2001
began the era of capsule endoscopy for day to day
[3,4]
clinical use .
The MiroCam (IntroCam, Seoul, South Korea) has a
12 h operating time as compared to 8 h of the Olympus
[3]
Endo Capsule and PillCam SB2 . Longer operating time
can reduce incomplete examination and may increase
[4]
[3]
diagnostic yield . Pioche et al found the MiroCam
to have comparable efficacy to the PillCam SB2. The
MiroCam uses human body communication for image
transmission as opposed to radiofrequency as does
[3]
the PillCam SB2 . In 2010, Given imaging introduced

WJG|www.wjgnet.com

Statistical analysis

For the comparison of baseline characteristics and
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as for indications for capsule endoscopy as shown in
Table 1. There were four categories of indications for
capsule endoscopy: anemia, obscure GI bleed, known
history of AVM, and “other”. The “other” category
included Crohn’s/ileitis, chronic nausea and vomiting,
abdominal pain, diarrhea, weight loss, evaluation for
carcinoid tumor, follow up of ileal intussusception,
history of small bowel polyp, and history of small
bowel obstruction.
The PillCam SB2-ex had a significantly higher
completion rate than the PillCam SB2 (88% vs 79.5%,
P = 0.03). The diagnostic yield was greater for PillCam
SB2 than PillCam SB2-ex, (48.5% vs 35%, P = 0.01),
with a greater rate of detection of AVMs (17.5% vs
9.5%, P = 0.03). Other findings were similar between
the two groups. The mean study lengths were 4:15:56
and 4:51:27 for PillCam SB2 and PillCam SB2-ex,
respectively. The most distal timestamp of a positive
finding for the PillCam SB2-ex (15:08:22) was longer
than that of the PillCam SB2 (7:24:21). For the PillCam
SB2, six cases found small bowel polyps and three
cases described a soft tissue lesion. In the PillCam
SB2-ex, two cases identified a duodenal mass, one
case a polypoid lesion in the jejunum, and one case a
duodenal polyp (Table 2).
Nine cases from the total SB2-ex capsule group
(200) had clinical significant findings beyond the 8 h
mark. These findings are summarized in Table 3. Of
these 9 cases, 4/70 (5.7%) of abnormal PillCam SB2ex small bowel findings occurred beyond 8 h.

Table 1 Demographics and indications for capsule endoscopy
in each capsule group n (%)
PillCam SB2 cases

PillCam SB2-ex
cases

P value
(< 0.05)

70.90 ± 14.19
91 (45.5)
131 (65.5)
47 (23.5)
178 (89)

71.93 ± 13.80
96 (48)
146 (73)
36 (18)
182 (91)

0.46
0.69
0.13
0.22
0.62

Age (mean ± SD)
Male
Obscure GI bleed
Anemia
Anemia or obscure
GI bleed
AVM
Other

11 (5.5)
11 (5.5)

9 (4.5)
9 (4.5)

0.82
0.82

GI: Gastrointestinal; AVM: Arteriovenous malformation.

1

Table 2 Characteristics and small bowel findings for each
capsule group n (%)
PillCam SB2 cases PillCam SB2-ex cases
Complete studies
Average
completed study
duration
Abnormal
finding total
Bleeding
AVM
Erosive disease
Polyp/mass (see
text)
Miscellaneous

P value
(< 0.05)

159 (79.5)
4:15:56

176 (88)
4:51:27

0.03

97 (48.5)

70 (35)

0.01

21 (10.5)
35 (17.5)
32 (16)
9 (4.5)

20 (10)
19 (9.5)
26 (13)
4 (2)

1.00
0.03
0.45
0.26

0

1 (1)

1.00

1

Some cases had multiple findings. AVM: Arteriovenous malformation.

DISCUSSION

Table 3 Clinically significant findings beyond the 8 h mark in
the SB2-ex capsule group
Findings outside of the
small bowel
Bleeding in colon

AVM in colon
Portal gastropathy

Time

Findings in the
small bowel

Time

8:59:18;
14:09:59;
15:08:22
8:59:34
10:38:06

Bleeding in
duodenal bulb due
to AVM
AVM
Denuded mucosa
in SB
Jejunitis

8:57:24

Since the introduction in 2003 of the M2A capsule,
capsule endoscopy has become a first line modality
[3,4]
for the evaluation of obscure GI bleed
. The
advancement of longer operating times is expected
to offer the potential of both increasing the rate
of completed studies and detecting more clinically
significant findings. Our findings do confirm that the
extra 4 h of operating time provided by the 12 h SB2ex resulted in a significantly higher rate of complete
studies over the 8 h SB2 capsule for an inpatient
population, 88% vs 79.5%, P = 0.03 respectively. Two
retrospective studies on 8- hour capsule performed
in Thailand and New Zealand demonstrated similar
[7,8]
completion rates as our PillCam SB2 group
.
Unfortunately the authors of the Thai study did not
delineate whether the population of patients involved
in the study were strictly inpatient-based, and the
patients included in the New Zealand study were
a mixed population of inpatients and outpatient.
Additionally, all patients received bowel preparations,
and some may have been given pro-motility agents.
This highlights a difference from our own study which
was performed exclusively in the inpatient population,
and was done without routine use of bowel prep or
pro-motility agents. Previously reported data have

9:34:04
11:15:22
13:02:13

AVM: Arteriovenous malformation.

outcome variables between the PillCam SB2 and
PillCam SB2-ex capsule groups, two sample unpaired
t-test for continuous variables and Fischer’s exact test
for categorical values were used. P value < 0.05 was
considered significant. GraphPad software was used for
all analysis. The statistical methods of this study were
reviewed by Meredith Akerman.

RESULTS
A total of 400 cases were reviewed. The two groups
were well matched for both age and gender as well

WJG|www.wjgnet.com
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found incompletion rates for 8 h capsule endoscopy
[4,6]
to be as high as 25% of all cases . These previous
results suggest that the difference we observed was
real, and not related to an abnormally low completion
rate in the SB2 group. Incomplete studies may be
due to battery/system failure before reaching the
cecum, though this was not the case in either the
SB2 or SB2-ex group. Other factors more commonly
affecting completion rate such as variable bowel
motility, delayed gastric emptying, capsule retention,
[2,9]
previous SB surgery, and poor bowel cleansing
likely accounted for the incomplete examinations in
both groups.
Despite the significantly higher study completion
rate, we were unable to demonstrate a superior
diagnostic yield for SB2-ex over SB2. In fact the
diagnostic yield between PillCam SB2 and PillCam
SB2-ex was 48.5% vs 35% (P value = 0.01), favoring
improved diagnostic yield for the 8 h PillCam SB2.
This unexpected finding would appear to challenge the
notion that a longer operating time translates into an
improvement in diagnostic yield. We suspect however
that the difference in diagnostic yield found in the
present study is related to the advancing/changing
expertise of the interpreting gastroenterologists
over time. As noted, the PillCam SB2 examinations
all occurred in the years 2009 to 2011 prior to the
PillCam SB2-ex examinations 2011 to 2013. It is
possible that over the time period studied that the
standards by which each of the gastroenterologists
qualified a finding as “positive” may have changed. It
is particularly notable that the largest classification of
significant finding by SB2 was AVMs, found in 17.5%
of studies, compared to 9.5% for the SB2-ex. Since
there is no gold standard for labeling a finding as an
AVM by capsule endoscopy it is possible that with more
practice, the reporters’ threshold to interpret AVMs
as a significant finding increased leading to less AVMs
reported, and a decreased diagnostic yield overall.
Though even if we accept a similar diagnostic
yield between the two capsule systems, there is
still a potential for improved cost effectiveness with
the 12 h system. Since extending the operating life
of the capsule resulted in more complete studies,
this would seem to offer a cost benefit by avoiding
repeating those studies which were incomplete, by
not prolonging the patient’s hospital admission to
repeat incomplete studies, and by limiting the need for
diagnostic imaging to confirm capsule passage which
is often required when visualization of the cecum is not
achieved during capsule recording.
While ours is the largest study to date, it is not
the first to address diagnostic yield of an 8 h vs a
[3,4]
[4]
12 h capsule . Kim et al found a nonsignificant
increased diagnostic yield with the 12 h MiroCam
capsule compared with the 8 h PillCam SB2 in 24
patients (45.8% vs 41.7%), with a completion rate
to the cecum which was higher. However, it should
be noted that the completion was rate for standard

WJG|www.wjgnet.com

PillCam SB in his study was very low at 58.3%. Pioche
[3]
et al performed a larger, multicentered, prospective,
randomized study also comparing the diagnostic
yield of the PillCam SB2 and MiroCam capsules in
83 patients. In patients having both examinations
completed, the MiroCam identified significantly more
findings than the PillCam SB2 capsules. However, a
more recently published study performed by Choi et
[10]
al , performed in a similar fashion with 105 patients,
was unable to show an improvement in diagnostic yield
for the MiroCam in comparison to the PillCam SB2,
and only showed a positive trend but not a statistical
difference in completion rates.
In our study, significant SB findings beyond 8 h
were identified in four cases by PillCam SB2-ex, 5.7%
of the total “positive” studies. While this yield beyond
8 h did not contribute to a significantly increased study
yield overall for the 12 h system, it is notable that such
a large percentage of significant findings occurred
beyond the standard 8 h window.
One issue that can occur particularly often in
hospitalized patients, is slowed or altered gastric
motility. A potential weakness of our study was the
lack of any control for this variable, as well as a lack
of data regarding potential prokinetic use by the study
population. Conversely we do know that prokinetic
use is not routine in our institution for capsule studies.
Given the overall demographic similarities between
the two groups it seems unlikely that prokinetic use
effected the study results if it was in fact utilized.
In two of the eight cases mentioned above, despite
the capsule retention in the stomach for a portion of
time equivalent to the complete battery life of the
PillCam-SB2, the additional battery life of the PillCam
SB2-EX allowed the capsule enough time to locate
a finding of clinical interest. Prokinetics have been
used to shorten small bowel transit time and possibly
[11]
improve completion rates . In a meta-analysis by
[11]
Koulaouzidis et al , a statistically higher completion
rate was found in patient who ingested the capsule
with metoclopramide vs control [OR (95%CI):
2.8 (1.35-3.21)]. In addition, a prospective study
comparing metoclopramide ingestion prior to capsule
endoscopy vs control found statistically significant
higher completion rates in the former group (97% vs
[12]
76%) . These studies were both performed using the
8-h capsules.
Additionally, bowel preparation can affect the
[13]
degree of visualization of the small bowel . Currently,
European guidelines advocate the use of a PEG
[14]
preparation for capsule endoscopy . It has been
shown that using a bowel prep in addition to a
prokinetic agent can increase completion rate, as
shown in a meta-analysis published by Koulaouzidis
[11]
et al . In Pioche’s study, polyethylene glycol (PEG)
was used for bowel cleanliness in patients receiving
[3]
the MiroCam or the PillCam SB2 . The diagnostic yield
was higher for the MiroCam when compared to PillCam
SB2. Our institution capsule protocol required each
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Innovations and breakthroughs

patient to have nothing but clear liquids from noon the
day before the examination and to receive “nothing by
mouth” the night prior to capsule ingestion. While no
specific purgative bowel preparation was required for
capsule examination, we know from standard practice
in the institution that many of these patients had their
study performed soon after a negative colonoscopy
which itself involved a bowel cleanse. As it was not
standard to address bowel purgative use prior to
capsule study in the capsule reports, it is unknown how
purgative use may have been a potential confounding
factor.
An additional limitation of our study is its nonrandomized nature, notably with the pre-procedure
indication of obscure GI bleeding differing between the
two groups. When including both obscure GI bleed and
anemia together as an indication, there was no longer
a statistical difference between the study groups.
There was also no control for the timing of capsule
endoscopy in these cases of obscure GI bleeding. Prior
studies have shown that capsule endoscopy performed
within the first few days of obscure GI bleed increases
[15-17]
the diagnostic yield
.
In our study, obscure GI bleeding was the major
indication for both PillCam SB2 (65.5%) and PillCam
SB2-ex (73%) capsule studies. In the PillCam SB2-ex
group, the most common findings were active small
bowel bleeding, erosive disease, and AVM with rates
of 10%, 13%, and 9.5%, respectively. Our findings
are similar to prior reports. In a large meta-analysis
involving 22840 capsule endoscopies, AVM was the
most common diagnosis for obscure GI bleed followed
[9]
by small bowel inflammation/ulcers .
In conclusion we have demonstrated superior
completion rates for the PillCam SB2-ex 12 h capsule
as compared to the 8 h PillCam SB2. We were unable
to demonstrate a superior overall diagnostic yield of
the 12 h system despite a notable number of clinically
significant findings detected beyond the 8 h mark,
including active bleeding, in the SB2-ex group. Further
prospective randomized studies will be needed to
confirm the advantage of PillCam SB2-ex over PillCam
SB2.

Prior studies have compared 12 h operating time capsules to 8 h capsules
but the capsules systems uses different image transmission system. The
PillCam SB2 and the PillCam SB2-ex have the same size and specifications
except for the recording time. The authors found the PillCam SB2-ex to have a
significantly increased completion rate, though without any improvement in the
diagnostic yield compared to the PillCam SB2.

Applications

Despite these findings, there were a small number of patients who had clinically
significant findings beyond the 8 h mark, implying a role for the longer-length
examination in a selected population. Additionally, the significantly increased
rate of successful, completed studies for the longer operating capsule should
offer a cost benefit over the older system.

Terminology

Capsule endoscopy refers to a miniature capsule shaped camera that takes
multiple pictures as its passes through the small intestine. Images are wirelessly
transmitted to a recording device which is attached to the patient. There are
different capsule endoscopy systems. PillCam SB2 is the older capsule with
an 8 h operating time, and PillCam SB2-ex is the newer capsule with a 12 h
operating time.

Peer-review

In this well written study the authors compared 12 h to 8 h camera and
identified that the 12 h camera was associated with higher completion rate
and 6% findings that were distal to the 8 h camera reach. Surprisingly, the
diagnostic yield of the 8 h camera was significantly higher. This is the largest
cohort to date and the results are certainly interesting.
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